Liver Enzymes, AST/ALT Ratio, and Synthetic Function
Interpret liver panels by separating injury pattern, tissue source, and function, then use the AST/ALT ratio without missing urgent disease.
AST 180 and ALT 60 give a ratio of three. That arithmetic does not tell you whether the AST came from liver or injured muscle, whether alcohol caused the illness, or whether the liver is failing. Read the panel in three dimensions before naming a disease.
Which question does each test answer?
The phrase liver function tests bundles together measurements with different jobs. Aminotransferases show cellular injury. Cholestatic enzymes help identify impaired bile flow. Albumin and clotting studies contribute information about protein production, while bilirubin reflects handling and excretion. Platelets may reveal consequences of portal hypertension, but are not a direct hepatic protein-synthesis assay. [1]
Read across the three dimensions of a liver panel.
Injury pattern
AST and ALT versus ALP, normalized to their own upper limits. Ask whether hepatocellular injury, cholestasis, or both predominate.
Tissue source
CK and the history help localize AST. GGT or ALP fractionation helps distinguish hepatic from bone ALP.
Function and consequences
INR, albumin, bilirubin, glucose, mental status, and platelets supply information the enzyme height cannot provide.
A person may have very high ALT with preserved function, or advanced cirrhosis with almost normal aminotransferases. These columns must be assessed independently. [1][2]
Start with stability. Check blood pressure, mental status, glucose, jaundice, bleeding, medication exposures, and signs of chronic disease. A new abnormal result in a well person can be confirmed and investigated systematically. New confusion, hypoglycemia, shock, or worsening coagulopathy cannot wait for a routine repeat panel.
Look at the trajectory as well as the number. Falling aminotransferases can reflect improvement, but a falling ALT accompanied by rising INR and worsening encephalopathy is not reassuring. In extensive necrosis, fewer viable hepatocytes may remain to release enzymes. Function and clinical course decide whether the liver is recovering. [3]
Calculate R before interpreting the enzyme pattern
The R factor compares the ALT multiple of its upper limit of normal with the ALP multiple of its upper limit. Use simultaneous values and the reporting laboratory's limits. Do not substitute AST, divide raw ALT by raw ALP, or put bilirubin in the formula.
R = (ALT / ALT upper limit) / (ALP / ALP upper limit).
R at or below 2
Cholestatic pattern. ALP predominates relative to its own reference limit.
R above 2 but below 5
Mixed pattern. Both hepatocellular and cholestatic components contribute.
R at or above 5
Hepatocellular pattern. ALT predominates relative to its own reference limit.
For ALT 360 U/L with upper limit 40 and ALP 180 U/L with upper limit 120, ALT is 9 times normal and ALP is 1.5 times normal. R is 6, a hepatocellular pattern. The raw ratio of 2 would give the wrong classification. R classifies an abnormal biochemical pattern, especially in suspected drug injury; it neither proves the culprit drug nor measures functional reserve. Ratios built from normal enzymes do not diagnose a liver disease. [1][4]
Pattern boundaries are useful conventions rather than biological cliffs. At R 2, classify the initial pattern as cholestatic; at R 5, classify it as hepatocellular. The pattern can change during illness. Record which sample you used and reassess new findings rather than forcing every subsequent result into the initial label.
Hepatocellular injury prompts consideration of viral hepatitis, drug or supplement toxicity, ischemia, autoimmune hepatitis, steatotic liver disease, and selected metabolic or vascular disorders. Cholestasis prompts investigation of obstruction, cholestatic drug injury, primary biliary cholangitis, primary sclerosing cholangitis, and other intrahepatic disorders. Drug injury can produce any of the three patterns. A mixed pattern is not proof that a patient has two separate diseases. [1][4]
Let the tissue context outrank the AST/ALT ratio
AST occurs in liver, skeletal muscle, heart, and red cells. ALT is more concentrated in liver but is not exclusive to it. Muscle injury can raise both, often with a larger AST increase. A recent crush injury, strenuous exercise, myalgia, weakness, or dark urine should prompt CK testing and evaluation of rhabdomyolysis. A high CK with normal bilirubin and ALP makes muscle a compelling source. It does not absolutely exclude a second hepatic process. [1]
An AST/ALT ratio above two can support alcohol-associated hepatitis when the patient has compatible recent heavy alcohol exposure and new jaundice. It is neither necessary nor sufficient. Alcohol-related mitochondrial injury and altered vitamin B6 availability help explain AST predominance, but the ratio is not a measurement of alcohol intake. The clinical criteria for probable alcohol-associated hepatitis use AST 50 to 400 U/L, an AST/ALT ratio above 1.5, bilirubin above 3 mg/dL, new jaundice within 60 days of heavy alcohol use exceeding 50 g/day for at least six months, and exclusion of competing causes. Values are often modest compared with ischemic or acetaminophen injury. [5] Marked values around a thousand require an expanded differential rather than being attributed automatically to alcohol.
Advanced cirrhosis from causes other than alcohol can also produce AST predominance. Conversely, normal enzymes do not exclude advanced fibrosis. A ratio slightly above one in a person whose AST and ALT are both normal should not be promoted into a diagnosis. Establish the exposure, chronic disease context, other laboratory abnormalities, and fibrosis risk. [1][5]
ALP needs its own source check. Bone turnover, growth, bone disease, and placental production can increase ALP. Concordant GGT supports hepatobiliary origin, but GGT itself is nonspecific and can rise with medications or alcohol exposure. It does not diagnose obstruction or alcohol-associated hepatitis alone. An isolated ALP increase with normal GGT favors a nonhepatic source; if the context is unclear, use ALP isoenzymes or further evaluation rather than declaring liver disease impossible. [1]
Separate excretion, synthesis, and portal effects
Bilirubin
Fractionate an isolated bilirubin increase. Predominantly unconjugated bilirubin suggests excess production, impaired uptake, or impaired conjugation. Hemolysis is supported by anemia, reticulocytosis, high LDH, and low haptoglobin. Intermittent isolated unconjugated bilirubin in an otherwise well person can fit Gilbert syndrome after appropriate exclusion of hemolysis and other causes. Conjugated bilirubin points toward impaired excretion from hepatocellular disease or cholestasis, not obstruction in every case. [1]
INR and albumin
Clotting factors have sufficiently short lifetimes that INR can change during acute loss of synthetic capacity. Interpret it with anticoagulant use, vitamin K deficiency, and disseminated intravascular coagulation in mind. In a jaundiced patient with poor intake or cholestasis, vitamin K deficiency can contribute. Improvement after replacement supports that contribution; a persistent rise with worsening illness raises concern for hepatic dysfunction. INR in cirrhosis is not a stand-alone prediction of bleeding risk because it does not capture the entire altered hemostatic system.
Albumin responds more slowly. Its approximate two- to three-week half-life means a normal albumin does not exclude abrupt severe injury. Low albumin may reflect chronic liver disease, inflammation, malnutrition, dilution, or renal or gastrointestinal loss. Low albumin with heavy proteinuria should not be called hepatic failure without further evidence. [1]
Platelets and architecture
Thrombocytopenia with a nodular liver and splenomegaly supports portal hypertension with splenic sequestration, often with additional contributions such as reduced thrombopoietin. Marrow suppression, medications, immune destruction, and consumption are alternatives. Interpret platelets alongside imaging and the rest of the blood count. Quiet aminotransferases do not undo evidence of abnormal liver architecture. [2][10]
Recognize results that change disposition
AST or ALT near or above 1,000 U/L should prompt urgent assessment for ischemic injury, acetaminophen or other toxic injury, acute viral hepatitis, and autoimmune or vascular causes. This is a focused differential, not an exclusive list. Acute bile duct obstruction can occasionally produce a striking transient aminotransferase rise before a cholestatic pattern dominates. A prospective study documented ALT at least 1,000 U/L in some patients with common duct stones. Biliary symptoms and imaging still matter. [3][6]
Shock and abrupt enzyme surge. Restore perfusion and oxygenation while assessing other contributors. Treat the hemodynamic cause, not merely the laboratory abnormality.
Possible acetaminophen injury. Obtain a concentration, establish timing and dose pattern, and start N-acetylcysteine promptly when indicated. A low or undetectable late level does not exclude toxicity. The ingestion nomogram is not valid for an unknown time or repeated supratherapeutic use. [7][8]
Fever, right upper quadrant pain, jaundice, and duct dilation. Suspect cholangitis. Begin resuscitation and antibiotics and arrange urgent drainage, generally endoscopic. ASGE suggests biliary decompression within 48 hours; unstable patients need urgent individualized source control rather than waiting for that endpoint. [9]
Acute injury developing within 26 weeks, INR at least 1.5, and hepatic encephalopathy without established cirrhosis. Treat as acute liver failure and contact a transplant center early. Coagulopathy without encephalopathy is serious acute liver injury but does not, by itself, meet the usual adult ALF definition. [3]
At each reassessment, state the pattern, likely tissue source, function, and next action separately. Repeat measurements should answer whether the cause is controlled and the patient is recovering, not simply whether one enzyme is lower.
Interpret the whole panel
Case 1
Show answer and explanations for case 1
A. R 1.5, cholestatic (Why this does not fit)
This is the ALP multiple alone, not R.
B. R 9, hepatocellular (Why this does not fit)
This uses the ALT multiple without dividing by the ALP multiple.
C. R 6, hepatocellular (Best answer)
ALT is 9 times ULN and ALP is 1.5 times ULN; 9 divided by 1.5 is 6.
D. R 2, cholestatic (Why this does not fit)
Two is the raw ALT/ALP ratio; both results must first be normalized.
A. Both results should change at the same rate because both assess synthesis (Why this does not fit)
Albumin and clotting factors have different lifetimes; their concentrations need not change together.
B. Vitamin K deficiency is established by normal albumin (Why this does not fit)
Vitamin K deficiency is a possible INR confounder, but normal albumin does not identify the cause; acute toxic injury can impair clotting-factor production.
C. Albumin's longer half-life makes it less responsive to abrupt injury (Best answer)
The INR can reveal acute synthetic impairment before albumin falls.
D. Normal albumin indicates that the INR cannot reflect hepatic dysfunction (Why this does not fit)
Albumin’s slower response cannot exclude acute loss of clotting-factor synthesis.
Takeaway: Different protein lifetimes create different laboratory response times.
